Could calcitonin gene‐related peptide inhibitors prevent status epilepticus?
Michael Nsaka, Noor Baban, Sepideh Allahdadian, Armin Scheffler, Diana Lindner, Dagny Holle, Alain Lekoubou · 2026
Read Could calcitonin gene‐related peptide inhibitors prevent status epilepticus? by Michael Nsaka, Noor Baban, Sepideh Allahdadian, Armin Scheffler, Diana Lindner, Dagny Holle, Alain Lekoubou (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13675781.txt.
Description
Michael Nsaka and six co-authors ask whether migraine drugs that block the peptide CGRP also cut the risk of a dangerous seizure state. Status epilepticus, a seizure that will not stop, is fed by brain inflammation, which CGRP helps drive. The team mined a network covering 130 health organizations for patients who have both epilepsy and migraine. They matched users and non-users of CGRP blockers on age, sex, seizure drugs, and other traits, leaving about eighteen thousand patients in each group.
The seizure emergency struck 2.41 percent of the drug group against 4.63 percent of the others, roughly half the risk. Hospital visits for the emergency were also fewer among users. The authors are careful: matching cannot prove the drugs caused the gap. They call for direct trials in patients who carry both diagnoses.
Catalog record
| CREATOR | Michael Nsaka, Noor Baban, Sepideh Allahdadian, Armin Scheffler, Diana Lindner, Dagny Holle, Alain Lekoubou |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 14 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |